Syros Pharmaceuticals Inc expected to post a loss of 87 cents a share - Earnings Preview

Syros Pharmaceuticals

06/05/2024 17:14

* Syros Pharmaceuticals Inc  SYRS.OQ   SYRS.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 8
(estimated) for the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 75.6% decrease in revenue to $720 thousand from $2.95 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Syros Pharmaceuticals
Inc is
for a loss of 87 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $14.00​, above​ its last closing price
of $5.13. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.31       -1.14      -2.18     Missed  -90.5
 Sep. 30 0001  -1.16       -1.14      -1.43     Missed  -25.3
 Jun. 30 2023  -1.10       -1.13      -1.30     Missed  -15.2​
 Mar. 31 2023  -1.10       -1.09      -0.85     Beat    22
 ​​Dec.        -1.36       -1.35      -0.17     Beat    87.4
 31 2022                                                
 Sep. 30 2022  -3.91       -4.01      -3.21     Beat    20​
 Jun. 30 2022  -3.92       -4.08      -5.40     Missed  -32.4
 Mar. 31 2022  -4.64       -4.70      -4.00     Beat    14.9
 This summary was machine generated May 6 at 16:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)